- Natera: A global leader in cell-free DNA testing
Natera advances molecular diagnostics with integrity and scientific rigor, and supports integration of information provided by our tests into health care decision making
- Natera - Wikipedia
Natera, Inc is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health
- Natera buys Foresight Diagnostics in $450M cancer testing deal
Natera is looking to grow its portfolio of tools to detect the recurrence of cancer with a deal to acquire Foresight Diagnostics, the Stanford University spinout and developer of blood tests for
- Natera Strengthens Cancer Detection Leadership with Strategic . . .
In a significant move to bolster its position in the oncology diagnostics market, Natera, Inc has announced the acquisition of Foresight Diagnostics The all-stock transaction, unveiled on December 5, includes an upfront payment of $275 million and potential additional earnouts of up to $175
- Portal Hub - Natera
Visit the appropriate Natera™ portal to check on results, schedule conversations with genetic counselors, place orders, or make payments
- Natera acquires Foresight Diagnostics for up to $450M
Natera last week said it completed the acquisition of Foresight Diagnostics, expanding the company’s position in solid tumor molecular residual disease detection, particularly in lymphoma, a cancer of the lymphatic system The all-stock transaction was valued at $275 million upfront, plus up to $
- Whats Going On With Natera Stock Friday? - Benzinga
Natera, Inc (NASDAQ: NTRA) on Friday acquired Foresight Diagnostics, a cancer diagnostics company, for $275 million upfront with an additional $175 million in earnouts tied to the achievement of
- Natera (NTRA): Assessing Valuation After a Powerful Multi‑Month Share . . .
Natera (NTRA) has quietly turned into one of the stronger movers in diagnostics this year, with the stock climbing roughly 21% over the past month and more than 40% in the past 3 months See our
|